PRESS RELEASE

16 September 2008

PFIZER SELECTS PROSONIX PROSONITRON™ SONOCRYSTALLIZATION TECHNOLOGY FOR PRIMARY API MANUFACTURING

Prosonix Ltd (Oxford, UK) is delighted to announce that Pfizer Global Manufacturing will implement Prosonix' Prosonitron™ reactor and sonocrystallization process technology at Pfizer's manufacturing facilities in Ireland.

The Prosonitron™ technology will be used in the controlled crystallization and production of a number of Pfizer products, and follows an extended period of collaboration and testing with Pfizer Global Research and Development in Sandwich (UK).

The Prosonitron™ technology is proven across scale, facilitating the Complete Crystallization Control™ of many aspects of complex pharmaceutical crystallization processes, including control of crystal size, shape, and purity, the selective production of polymorphs, enhancing both manufacturing productivity and ultimate formulation performance of drug product. The technology is increasingly being recognised as an important new option in pharmaceutical API crystallization.

Commenting on the deal, Prosonix CEO David Hipkiss said,

"I am delighted to be able to announce our latest pharmaceutical related deal with Pfizer. It further underscores our unique ability and leadership in taking advanced ultrasonic particle engineering technologies to commercial scale in the key pharmaceutical sector. In addition I would also like to compliment and expressly acknowledge the Pfizer Material Science Group at Sandwich (UK) for their continued and excellent support over a three year period, which has resulted in the adoption of our technology by the Pfizer manufacturing organisation today. We look forward to working with Pfizer in the months and years ahead to deliver significant and lasting benefit across their drug portfolio."

Commenting on the deal, Simon Davidson, New Product Team Leader, Pfizer Global Manufacturing said,

Sonocrystallization technology offers an additional tool to augment existing techniques for API crystallization and in-situ selection of specific API physical characteristics. We look forward to working with the Prosonix team to implement this technology in Pfizer Global Manufacturing.

For more Information contact:

Prosonix

David Hipkiss
CEO
Prosonix Ltd
Magdalen Centre
Oxford Science Park
Oxford
OG4 4GA, UK

Tel + 44 (0) 1865 784250
Web www.prosonix.co.uk

PRESS RELEASE

Prosonix
Experts in Sound Science™

Notes for Editors

About Prosonix Ltd www.prosonix.co.uk

Based in Oxford UK and Experts in Sound Science™, Prosonix are acknowledged leaders in the commercialization of proprietary ultrasonic particle engineering technologies and added value ultrasonic process chemistry solutions for the pharmaceutical and related industries.

Prosonix's team of chemists and engineers combine to give Prosonix a unique multidisciplinary approach and competitive advantage to solve customers complex particle engineering process problems, leveraging it's proprietary intellectual property and patented ultrasonic processing equipment to deliver long term and sustainable value added solutions, enabling the cost effective manufacture of better medicines.

Prosonix's core markets are in the Pharmaceutical and Chemical industries, having secured over 50 worldwide customers to date.

Prosonitron™, Prosonix's world leading patented sonocrystallization process and reactor technology is already proven across scale, facilitating the Complete Crystallization Control™ of many aspects of complex pharmaceutical crystallization processes, including control of crystal size, shape, purity, the selective production of polymorphs, enhancing both manufacturing productivity and ultimate formulation performance. New and proprietary process variants include DISCUS™ for the advanced particle engineering of microcrystalline active ingredients. At commercial scale the Prosonitron™ technology is increasingly being recognised as a potential first choice option in pharmaceutical API crystallization and isolation, with concomitant and quantitative benefits in formulation performance.

SAX™, an award winning sonocrystallization development, is a novel ultrasonic particle engineering and drug delivery technology with world beating potential, and builds on Prosonix core Prosonitron™ technology. SAX™ can produce highly engineered single and combination microcrystalline drug particles that are ideally suited for inhalation, without the need for destructive milling or micronisation processes. SAX™ particles have better stability, formulation consistency, eliminates dose-to-dose variation and exhibit potentially improved efficacy per unit dose than those made by other techniques. Prosonix in-licensed the SAX™ technology from the University of Bath on a world wide exclusive basis in February 2007.

In January 2008 Prosonix in-licensed a novel particle rounding technology process patent from Rafael Industries(Haifa, Israel) Importantly the process patent is already granted in key geographies and has wide ranging utility independent of the method of ultrasound delivery in secondary particle engineering, post initial crystallization and isolation. Key applications include particle rounding to improve product flowability and rheology, compressibility, and added concomitant benefits in formulation performance and assurance. Additional opportunities in taste masking, coating, and granulation are also emerging. Used in combination, the Rafael process technology and the proven Prosonix Prosonitron™ process and reactor technology represents an ideal solution to a range of common secondary pharmaceutical manufacturing problems associated with API's and excipients with quantitative benefits in formulation performance.

Underpinning Prosonix's leadership in commercializable crystallization technology is CrystalGEM™, an award winning predictive crystallization service that significantly enhances crystallization screening productivity in pharmaceutical development. In addition a new range of designed for purpose small scale SonoLab™ equipment is now available for laboratory and kilo lab use. Unlike other laboratory systems SonoLab's™ transducer based design can be used by the laboratory chemist with confidence, allowing a seamless transition across scale to proven Prosonitron™ based commercial manufacture.

Complementing its market led internal R&D programs, Prosonix is also actively engaged with several strategic partnerships with leading academic and technology institutions, including the University of Bath, University of Coventry, and the University of Leeds. Prosonix is further supported by leading industrial and academic consultants including but not limited to Dr Rob Price (University of Bath, UK), Dr Kevin Roberts (University of Leeds, UK) and Professor Tim Mason (University of Coventry).

In November 2007 Prosonix successfully completed a £5 million total funding round designed to underpin and drive the accelerated future growth plans of the business. New investors in the round were led by Solon Ventures LP advised by Solon Ventures Ltd (London, UK), joined by The Entrepreneurs Fund BV (Amsterdam, Netherlands) and Quest for Growth (Leuven, Belgium), and supported by the existing Investors.

---------- ENDS -------